Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone +/- subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial
Por:
Terpos, E, Dimopoulos, MA, Boccadoro, M, Delimpasi, S, Beksac, M, Katodritou, E, Moreau, P, Pompa, A, Symeonidis, A, Bila, J, Oriol, A, Mateos, MV, Einsele, H, Orfanidis, I, Gries, KS, Fastenau, J, Liu, K, He, JM, Kampfenkel, T, Qiu, YP, Amin, H, Carson, R and Sonneveld, P
Publicada:
1 abr 2022
Ahead of Print:
1 feb 2022
Resumen:
In the phase 3 APOLLO trial, daratumumab in combination with pomalidomide and dexamethasone (D-Pd) significantly reduced the rate of disease progression or death by 37% relative to Pd alone in patients with relapsed/refractory multiple myeloma (RRMM) who had received >= 1 prior line of therapy including lenalidomide and a proteasome inhibitor. Here, we present patient-reported outcomes (PROs) from APOLLO. Median treatment duration was 11.5 months with D-Pd and 6.6 months with Pd. PRO compliance rates were high and similar in both groups. No changes from baseline were observed for EORTC QLQ-C30 global health status scores in either group, while physical and emotional functioning, disease symptoms, and adverse effects of treatment remained at baseline levels with D-Pd but worsened with Pd. Reductions (p < 0.05) in pain and fatigue were seen at several time points with D-Pd versus Pd. Overall, these results suggest patients' health-related quality of life remained stable when daratumumab was added to Pd, with several results favoring D-Pd versus Pd. These findings complement the significant clinical improvements observed with D-Pd and support its use in patients with RRMM.
Filiaciones:
Terpos, E:
Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Athens, Greece
Dimopoulos, MA:
Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Athens, Greece
Boccadoro, M:
Univ Torino, Dept Mol Biotechnol & Hlth Sci, Turin, Italy
Delimpasi, S:
Evangelismos Med Ctr, Dept Hematol, Athens, Greece
Beksac, M:
Ankara Univ, Dept Hematol, Ankara, Turkey
Katodritou, E:
Theagenio Canc Hosp, Dept Hematol, Thessaloniki, Greece
Moreau, P:
Univ Hosp Hotel Dieu, Hematol Dept, Nantes, France
Pompa, A:
Univ Milan, Hematol Unit, Milan, Italy
Symeonidis, A:
Univ Patras, Dept Internal Med, Patras, Greece
Bila, J:
Univ Belgrade, Clin Hematol, Belgrade, Serbia
:
Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain
Mateos, MV:
Univ Hosp Salamanca, Hematol Dept, IBSAL, Canc Res Ctr IBMCC USAL CSIC, Salamanca, Spain
Einsele, H:
Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany
Orfanidis, I:
Hlth Data Specialists SA, Dublin, Ireland
Gries, KS:
Janssen Res & Dev LLC, Seattle, WA USA
Fastenau, J:
Janssen Res & Dev LLC, Raritan, NJ USA
Liu, K:
Janssen Res & Dev LLC, Raritan, NJ USA
He, JM:
Janssen Res & Dev LLC, Raritan, NJ USA
Kampfenkel, T:
Janssen Res & Dev LLC, Leiden, Netherlands
Qiu, YP:
Janssen Res & Dev LLC, Beijing, Peoples R China
Amin, H:
Janssen Res & Dev LLC, Raritan, NJ USA
Carson, R:
Janssen Res & Dev LLC, Wayne, PA USA
Sonneveld, P:
Erasmus MC, Dept Hematol, Canc Inst, Rotterdam, Netherlands
|